![\"\"\/](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/07\/ea029964501_ex99-1img1.jpg\")
\u00a0<\/p>\n\u00a0<\/p>\n
UNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\u00a0<\/p>\n
Form 6-K<\/p>\n
\u00a0<\/p>\n
Report of Foreign Private Issuer<\/p>\n
Pursuant to Rule 13a-16 or 15d-16<\/p>\n
under the Securities Exchange Act of 1934<\/p>\n
\u00a0<\/p>\n
For the month of July 2026 (Report No. 2)<\/p>\n
\u00a0<\/p>\n
Commission File Number: 001-38041<\/p>\n
\u00a0<\/p>\n
SCISPARC LTD.<\/p>\n
(Translation of registrant\u2019s name into English)<\/p>\n
\u00a0<\/p>\n
20 Raul Wallenberg Street, Tower A,<\/p>\n
Tel Aviv 6971916 Israel<\/p>\n
(Address of principal executive offices)<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F:<\/p>\n
\u00a0<\/p>\n
Form 20-F \u2612\u00a0\u00a0\u00a0\u00a0\u00a0Form
\n40-F \u2610<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
CONTENTS<\/p>\n
\u00a0<\/p>\n
On July 27, 2026, SciSparc
\nLtd.\u00a0(the \u201cCompany\u201d) issued a press release titled \u201cSciSparc Announces Decision to Target the Agentic AI Market;
\nForms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.\u201d On July 29, 2026, the Company issued a press release
\ntitled \u201cSciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P
\n500 company.\u201d Copies of these press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report
\nof Foreign Private Issuer on Form 6-K (this \u201cReport\u201d) and is incorporated by reference herein.<\/p>\n
\u00a0<\/p>\n
This Report is incorporated
\nby reference into the Company\u2019s registration statements on Form F-3 (File Nos.\u00a0333-286099,\u00a0333-275305,\u00a0333-269839,\u00a0333-266047,\u00a0333-248670,\u00a0333-255408,\u00a0333-293167\u00a0and\u00a0333-293533)
\nand on Form S-8 (File Nos.\u00a0333-278437,\u00a0333-225773,\u00a0333-286791\u00a0and\u00a0333-292952)
\nfiled with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent
\nnot superseded by documents or reports subsequently filed or furnished.\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
EXHIBIT INDEX<\/p>\n
\u00a0<\/p>\n
Exhibit No.
\n \u00a0
\n Description<\/p>\n
99.1
\n \u00a0
\n Press release issued by SciSparc Ltd. titled \u201cSciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.\u201d<\/p>\n
99.2
\n \u00a0
\n Press release issued by SciSparc Ltd. titled \u201cSciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company.\u201d<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
Pursuant to the requirements
\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
\nduly authorized.<\/p>\n
\u00a0<\/p>\n
\u00a0
\n SCISPARC LTD.<\/p>\n
\u00a0
\n \u00a0
\n \u00a0<\/p>\n
\u00a0
\n By:
\n \/s\/ Oz Adler<\/p>\n
\u00a0
\n Name:\u00a0
\n Oz Adler<\/p>\n
\u00a0
\n Title:
\n Chief Executive Officer and Chief Financial Officer<\/p>\n
\u00a0<\/p>\n
Date: July 29, 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Exhibit 99.1<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SciSparc Announces Decision to Target the Agentic AI Market; Forms
\nScientific Advisory Board for Artificial Intelligence and Cybersecurity<\/p>\n
\u00a0<\/p>\n
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:
\nSPRC) (\u201cCompany\u201d or \u201cSciSparc\u201d), today announced that its board of directors has made a decision to target the
\nagentic artificial intelligence (\u201cAI\u201d) market.<\/p>\n
\u00a0<\/p>\n
As part of this initiative, the Company has decided to establish a
\nScientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with
\nseveral companies active in the agentic AI field.<\/p>\n
\u00a0<\/p>\n
About SciSparc Ltd. (Nasdaq: SPRC):<\/p>\n
\u00a0<\/p>\n
The Company, through its majority-owned subsidiary NeuroThera, engages
\nin clinical-stage pharmaceutical developments. SciSparc\u2019s focus is on creating and enhancing a portfolio of technologies and assets
\nbased on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently
\nengaged in the following drug development programs based on THC and\/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome,
\nfor the treatment of Alzheimer\u2019s disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus.
\nThe Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based
\nproducts on the\u00a0Amazon.com\u00a0Marketplace.<\/p>\n
\u00a0<\/p>\n
Forward-Looking Statements:<\/p>\n
\u00a0<\/p>\n
This press release contains forward-looking statements within the meaning
\nof the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws.
\nFor example, SciSparc uses forward-looking statements when it discusses the opportunities available to it in the agentic AI market. However,
\nthe Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated
\nby the formation of the Scientific Advisory Board. Because such statements deal with future events and are based on SciSparc\u2019s current
\nexpectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ
\nmaterially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied
\nin this press release are subject to other risks and uncertainties, including those discussed under the heading \u201cRisk Factors\u201d
\nin SciSparc\u2019s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities
\nand Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
\nstatements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
\notherwise.<\/p>\n
\u00a0<\/p>\n
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055<\/p>\n
\u00a0<\/p>\n
Exhibit 99.2<\/p>\n
\u00a0<\/p>\n
\u00a0![\"\"\/](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/07\/ea029964501_ex99-2img1.jpg\")
<\/p>\n
\u00a0<\/p>\n
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform
\nfor Clinical Data Analytics on a Platform of an S&P 500 company<\/p>\n
\u00a0\u00a0<\/p>\n
TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:
\nSPRC) (\u201cCompany\u201d or \u201cSciSparc\u201d), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (\u201cNeuroThera\u201d),
\na clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has successfully
\ncompleted internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the \u201cPlatform\u201d).<\/p>\n
\u00a0<\/p>\n
The validated workflow enables continuous probability distributions
\nto be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500
\ncompany platform for hybrid quantum-classical computing. The validation supports a key component of the Platform\u2019s computational architecture
\nand is expected to further expand the Platform\u2019s capabilities for addressing complex analytical challenges involving large-scale
\nclinical and biomedical datasets.<\/p>\n
\u00a0<\/p>\n
Many real-world challenges in healthcare, life sciences, drug development
\nand advanced analytics are naturally represented as continuous probability distributions.\u00a0 The Platform\u2019s proprietary methodology
\nconverts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov
\nChain Monte Carlo (\u201cQMCMC\u201d) techniques while preserving the statistical characteristics of the original data.<\/p>\n
\u00a0<\/p>\n
By using the Platform, quantum dynamics generate proposed samples while
\na classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous
\ndatasets to be explored through quantum-generated proposals while maintaining established statistical guarantees.<\/p>\n
\u00a0<\/p>\n
The validated workflow represents an important step toward enabling
\nincreasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. NeuroThera believes
\nefficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational
\napproaches for healthcare and life sciences.<\/p>\n
\u00a0<\/p>\n
The Platform is being advanced through CliniQuantum, a quantum-focused
\ntechnology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%.<\/p>\n
\u00a0<\/p>\n
About SciSparc Ltd. (Nasdaq: SPRC):<\/p>\n
\u00a0<\/p>\n
The Company, through its majority-owned subsidiary NeuroThera, engages
\nin clinical-stage pharmaceutical developments. SciSparc\u2019s focus is on creating and enhancing a portfolio of technologies and assets
\nbased on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently
\nengaged in the following drug development programs based on THC and\/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome,
\nfor the treatment of Alzheimer\u2019s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus.
\nThe Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based
\nproducts on the\u00a0Amazon.com\u00a0Marketplace.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
About\u00a0NeuroThera\u00a0Labs Inc.<\/p>\n
\u00a0<\/p>\n
NeuroThera is a clinical-stage pharmaceutical company focused on developing
\nnovel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative
\ncombinations.<\/p>\n
\u00a0<\/p>\n
Forward-Looking Statements:<\/p>\n
\u00a0<\/p>\n
This press release contains forward-looking statements within the meaning
\nof the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws.
\nFor example, SciSparc uses forward-looking statements when it discusses the anticipated capabilities, performance, scalability and utility
\nof NeuroThera\u2019s quantum platform and of the validated quantum sampling workflow; the belief that efficient representation of continuous
\ndata within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life
\nsciences; the expectation that quantum computing technologies will continue to evolve in a manner that supports increasingly sophisticated
\nanalytical capabilities; the applicability of the platform to clinical, biomedical and drug development datasets; the continued development
\nof the platform through CliniQuantum; NeuroThera\u2019s ownership interest in CliniQuantum; and NeuroThera\u2019s business objectives,
\nplans and strategy generally.. Because such statements deal with future events and are based on SciSparc\u2019s current expectations,
\nthey are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially
\nfrom those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
\npress release are subject to other risks and uncertainties, including those discussed under the heading \u201cRisk Factors\u201d in
\nSciSparc\u2019s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities
\nand Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
\nstatements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
\notherwise.<\/p>\n
\u00a0<\/p>\n
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055<\/p>\n
\u00a0\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 Form 6-K \u00a0 Report of Foreign Private…\n","protected":false},"author":2,"featured_media":120759,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[179,7493,62216,41489,62215,1721,2844,61111,61112],"class_list":["post-123465","post","type-post","status-publish","format-standard","has-post-thumbnail","category-agentic-ai","tag-agentic-ai","tag-agentic-artificial-intelligence","tag-clinical-data-analytics","tag-form-6-k","tag-neurothera","tag-pharmaceuticals","tag-quantum-computing","tag-scisparc","tag-sprc"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/123465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=123465"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/123465\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/120759"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=123465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=123465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=123465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}